Page 8«..78910..2030..»

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

By Dr. Matthew Watson

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:

See the original post here:
Structure Therapeutics Announces Participation in Upcoming Investor Conferences

To Read More: Structure Therapeutics Announces Participation in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Structure Therapeutics Announces Participation in Upcoming Investor Conferences | dataAugust 27th, 2024
Read All

Notable Labs Announces CEO Transition

By Dr. Matthew Watson

Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO

Read the original here:
Notable Labs Announces CEO Transition

To Read More: Notable Labs Announces CEO Transition
categoriaGlobal News Feed commentoComments Off on Notable Labs Announces CEO Transition | dataAugust 27th, 2024
Read All

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

By Dr. Matthew Watson

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

Follow this link:
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

To Read More: Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
categoriaGlobal News Feed commentoComments Off on Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer | dataAugust 27th, 2024
Read All

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

By Dr. Matthew Watson

MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.

Read the original here:
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

To Read More: Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
categoriaGlobal News Feed commentoComments Off on Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference | dataAugust 27th, 2024
Read All

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

By Dr. Matthew Watson

Richard Stewart reassumes role of Chief Executive Officer

Read more here:
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

To Read More: Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
categoriaGlobal News Feed commentoComments Off on Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors | dataAugust 27th, 2024
Read All

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

By Dr. Matthew Watson

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that it received formal notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Q2 Quarterly Report”).

See the article here:
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

To Read More: Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
categoriaGlobal News Feed commentoComments Off on Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) | dataAugust 27th, 2024
Read All

IO Biotech Announces Participation in Upcoming Investor Conferences

By Dr. Matthew Watson

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences:

Excerpt from:
IO Biotech Announces Participation in Upcoming Investor Conferences

To Read More: IO Biotech Announces Participation in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on IO Biotech Announces Participation in Upcoming Investor Conferences | dataAugust 27th, 2024
Read All

BioSyent Declares Third Quarter 2024 Dividend

By Dr. Matthew Watson

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

Read more:
BioSyent Declares Third Quarter 2024 Dividend

To Read More: BioSyent Declares Third Quarter 2024 Dividend
categoriaGlobal News Feed commentoComments Off on BioSyent Declares Third Quarter 2024 Dividend | dataAugust 27th, 2024
Read All

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

By Dr. Matthew Watson

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks.

Continue reading here:
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

To Read More: Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
categoriaGlobal News Feed commentoComments Off on Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors | dataAugust 27th, 2024
Read All

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

By Dr. Matthew Watson

Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio

Here is the original post:
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

To Read More: Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
categoriaGlobal News Feed commentoComments Off on Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. | dataAugust 27th, 2024
Read All

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

By Dr. Matthew Watson

TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time.

See the original post here:
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

To Read More: Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference | dataAugust 27th, 2024
Read All

BioSyent Releases Financial Results for Q2 and H1 2024

By Dr. Matthew Watson

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2024. Key highlights include:

Here is the original post:
BioSyent Releases Financial Results for Q2 and H1 2024

To Read More: BioSyent Releases Financial Results for Q2 and H1 2024
categoriaGlobal News Feed commentoComments Off on BioSyent Releases Financial Results for Q2 and H1 2024 | dataAugust 27th, 2024
Read All

Telix Announces Reorganisation to Deliver on Strategic Priorities

By Dr. Matthew Watson

MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.

Visit link:
Telix Announces Reorganisation to Deliver on Strategic Priorities

To Read More: Telix Announces Reorganisation to Deliver on Strategic Priorities
categoriaGlobal News Feed commentoComments Off on Telix Announces Reorganisation to Deliver on Strategic Priorities | dataAugust 27th, 2024
Read All

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology Enhancements to Expand Capacityand New Business Opportunities –

Read more:
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update

To Read More: Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update | dataAugust 27th, 2024
Read All

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

By Dr. Matthew Watson

Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to, or have been previously treated with C5 inhibitors. PNH is a rare and life-threatening blood condition where red blood cells are destroyed by the complement system – part of the innate immune system – causing symptoms such as anaemia, fatigue and blood clots, and potentially leading to kidney disease.4

See the original post:
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

To Read More: Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
categoriaGlobal News Feed commentoComments Off on Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH | dataAugust 27th, 2024
Read All

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

By Dr. Matthew Watson

Ad Hoc Announcement Pursuant to Art. 53 LR

Original post:
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

To Read More: Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
categoriaGlobal News Feed commentoComments Off on Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration | dataAugust 27th, 2024
Read All

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

By Dr. Matthew Watson

WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA’s common stock, payable on August 28, 2024, to ARCA’s stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA’s Board of Directors on August 16, 2024, in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA’s reasonable, good faith approximation of the amount by which ARCA’s net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.

Go here to see the original:
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

To Read More: ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
categoriaGlobal News Feed commentoComments Off on ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics | dataAugust 27th, 2024
Read All

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore

By Dr. Matthew Watson

COPENHAGEN, Denmark, August 27, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that Singapore’s medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS® (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.

Read more:
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore

To Read More: Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore
categoriaGlobal News Feed commentoComments Off on Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore | dataAugust 27th, 2024
Read All

Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

By Dr. Matthew Watson

PRESS RELEASE

More:
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

To Read More: Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
categoriaGlobal News Feed commentoComments Off on Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy | dataAugust 27th, 2024
Read All

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers…

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR

More:
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers...

To Read More: European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers…
categoriaGlobal News Feed commentoComments Off on European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers… | dataAugust 27th, 2024
Read All

Page 8«..78910..2030..»


Copyright :: 2024